Invezz is an independent platform with the goal of helping users achieve financial freedom. In order to fund our work, we partner with advertisers who compensate us for users that Invezz refers to their services. While our reviews and assessments of each product on the site are independent and unbiased, brands may pay to appear higher up our table rankings or place ads in specific areas of the site. The order in which products and services appear on Invezz does not represent an endorsement from us, and please be aware that there may be other platforms available to you than the products and services that appear on our website. Read more about how we make money >
Latest breaking stories, features and analysis
- Biogen shares fell on Monday after the company announced crucial data for tofersen study.
- The Phase 3 trial for tofersen in patients ALS did not meet primary endpoints with statistical significance.
- The company will focus on broadening the access to experimental therapy on all eligible ALS patients.